Reframing the role of neuromodulation therapy in the chronic pain treatment paradigm

Krishnan Chakravarthy; Laxmaiah Manchikanti; Alan David Kaye; Paul J. Christo

Reframing the role of neuromodulation therapy in the chronic pain treatment paradigm

Krishnan Chakravarthy, Laxmaiah Manchikanti, Alan David Kaye, Paul J. Christo

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	507-513
Number of pages	7
Journal	Pain physician
Volume	21
Issue number	6
State	Published - Nov 2018

ASJC Scopus subject areas

Anesthesiology and Pain Medicine

Cite this

@article{7363c3453f384bf19d2fd0dee95f0fe2,

title = "Reframing the role of neuromodulation therapy in the chronic pain treatment paradigm",

author = "Krishnan Chakravarthy and Laxmaiah Manchikanti and Kaye, {Alan David} and Christo, {Paul J.}",

note = "Funding Information: Disclaimer: There was no external funding in the preparation of this manuscript. Conflict of interestDr. Chakravarthy is a consultant to Abbott formerly St. Jude Medical, Medincell, and Bioness. Dr. Manchikanti has provided limited consulting services to Semnur Pharmaceuticals, Incorporated, which is developing nonparticulate steroids. Dr. Kaye is a speaker for Depomed, Inc. and Merck. Dr. Paul Christo has no conflict of interest to declare.",

year = "2018",

month = nov,

language = "English (US)",

volume = "21",

pages = "507--513",

journal = "Pain physician",

issn = "1533-3159",

publisher = "Association of Pain Management Anesthesiologists",

number = "6",

}

TY - JOUR

T1 - Reframing the role of neuromodulation therapy in the chronic pain treatment paradigm

AU - Chakravarthy, Krishnan

AU - Manchikanti, Laxmaiah

AU - Kaye, Alan David

AU - Christo, Paul J.

N1 - Funding Information: Disclaimer: There was no external funding in the preparation of this manuscript. Conflict of interestDr. Chakravarthy is a consultant to Abbott formerly St. Jude Medical, Medincell, and Bioness. Dr. Manchikanti has provided limited consulting services to Semnur Pharmaceuticals, Incorporated, which is developing nonparticulate steroids. Dr. Kaye is a speaker for Depomed, Inc. and Merck. Dr. Paul Christo has no conflict of interest to declare.

PY - 2018/11

Y1 - 2018/11

UR - http://www.scopus.com/inward/record.url?scp=85060037429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060037429&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 30508982

AN - SCOPUS:85060037429

SN - 1533-3159

VL - 21

SP - 507

EP - 513

JO - Pain physician

JF - Pain physician

IS - 6

ER -

Reframing the role of neuromodulation therapy in the chronic pain treatment paradigm

ASJC Scopus subject areas

Other files and links

Cite this